Highlighting the need for individualized treatment strategies remains crucial, as the heterogeneous nature of APRIL’s impact on different B cell subsets across autoimmune diseases complicates the establishment of a uniform therapeutic approach. Tailored strategies could enhance efficacy and minimize adverse effects in patients with complex autoimmune profiles. The gene discussed is TNFSF13; the disease is autoimmune disease.